Enisamium Could be a Potential Treatment for COVID-19

Researchers from the USA and Europe have demonstrated that the influenza drug enisamium could be a potential treatment for SARS-CoV-2 infection. Enisamium is clinically approved for use against influenza in 11 countries. The researchers revealed that enisamium could inhibit the growth of SARS-CoV-2 in normal human bronchial epithelial cells and a human colon epithelial cancer cell line. They also conducted an in vitro assay showing that the metabolite VR17-04 directly inhibits the RNA synthesis activity of the SARS-CoV-2 nsp12/7/8 complex.

The research team conducted a double-blind, randomized, placebo-controlled trial of 373 hospitalized COVID-19 patients who need medical care. Participants received either enisamium (500 mg per dose) or placebo for 7 days. An interim analysis showed that among those who required supplementary oxygen (n=77), enisamium significantly improved the meantime to recovery, compared with placebo (11.1 versus 13.9 days). The researchers say the findings suggest that enisamium is an inhibitor of SARS-CoV-2 RNA synthesis and shortens recovery time among COVID-19 patients who require oxygen supplementation.

To know more about origin, virology of COVID-19, Click here

To know more about emerging themes in COVID-19, Click here

To know more about how WhiteCoats can help you in your professional advancement, visit www.whitecoats.com

Want to set up an online consultation for your practice, Click here

Ref link: https://www.medrxiv.org/content/10.1101/2021.01.05.21249237v1